Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 August 2023 | Story NONSINDISO QWABE | Photo SUPPLIED
Apartheid Studies, A Manifesto Book Launch
Prof Nyasha Mboti launched his book, Apartheid Studies: A Manifesto, on the UFS Qwaqwa Campus on 25 July 2023.

in a perpetual state of disaster and creating a normalised life, even if it is built on anomalous arrangements, Prof Nyasha Mboti launched his newly published book, Apartheid Studies: A Manifesto, on the UFS Qwaqwa Campus on 25 July 2023.

Prof Mboti is an Associate Professor and Head of the Department of Communication Science at the University of the Free State and is the pioneer and founder of Apartheid Studies, a new interdisciplinary field of study from the Global South, which utilises the notion of ‘apartheid’ as a paradigm by which to understand the confounding persistence and permanence of harm, oppression, and injustice.

Oppressive systems persist in modern South Africa

Making reference to the pass laws that were a dominant form/tool of oppression and segregation during the country’s apartheid system, he said apartheid created a “paradigm of life where things that aren’t supposed to go on, go on. 
Life has to go on even in oppression. People have the capacity to live with harm, and apartheid banks on people’s capacity to go on”.

The daring book posits itself as a first-of-its-kind authoritative study of the phenomenon of apartheid, shedding light on the continuing impact of apartheid decades after its formal abolishment and exploring the idea that while it was intended as a temporary phenomenon, it became deeply ingrained and normalised, persisting in various forms today.

“What apartheid is, is a temporary phenomenon that has become permanent. That is my argument. This book is an attempt to leverage how we live with harm as a way of doing something about it and hopefully putting an end to it. If you can go on one day living in harm and the next, before you know it, four decades of living under Apartheid from day to day have passed. Until we understand it, it persists,” he said.

By asking whether one would queue for a dompas, Prof Mboti challenged the audience to reflect on how oppressive systems persist when normalised, even when inflicting profound harm. 
“Would you queue for a dompas? If your answer is yes, then for me, that is an indication that Apartheid persists. Harm persists. Until we understand it, it persists.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept